Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats by Loch, David et al.
Journal of Cardiovascular Pharmacology 
 
ROSUVASTATIN ATTENUATES HYPERTENSION-INDUCED 
CARDIOVASCULAR REMODELLING WITHOUT AFFECTING BLOOD 
PRESSURE IN DOCA-SALT HYPERTENSIVE RATS 
 
David Loch1, Scott Levick1, Andrew Hoey2 and Lindsay Brown1 
 
 
1 Department of Physiology and Pharmacology, School of Biomedical Sciences, 
The University of Queensland 4072, AUSTRALIA 
2 Centre for Biomedical Research, Faculty of Sciences, University of Southern 
Queensland, Toowoomba 4350, AUSTRALIA 
 
Address for Correspondence: 
Assoc Prof Lindsay Brown, Department of Physiology and Pharmacology, School of 
Biomedical Sciences, The University of Queensland 4072, AUSTRALIA; telephone +61 
7 3365 3098; fax +61 7 3365 1766; email l.brown@uq.edu.au
 
Short Title: 
Rosuvastatin and remodelling in DOCA-salt rats 
 
Sources of Support: 
This study was supported in part by a grant from AstraZeneca, Macclesfield, Cheshire 
U.K. 
 
 
 
 1
ABSTRACT 
 
 
The pleiotropic effects of statins represent potential mechanisms for the treatment of end-
organ damage in hypertension. This study has investigated the effects of rosuvastatin in a 
model of cardiovascular remodelling, the DOCA-salt hypertensive rat. Male Wistar rats 
weighing 300-330g were uninephrectomized (UNX) or uninephrectomized and treated 
with DOCA (25 mg subcutaneously every fourth day) and 1% NaCl in the drinking 
water. Compared with UNX controls, DOCA-salt rats developed hypertension, 
cardiovascular hypertrophy, inflammation with perivascular and interstitial cardiac 
fibrosis, endothelial dysfunction and prolongation of ventricular action potential duration 
at 28 days. Rosuvastatin treated rats received 20mg/kg/day of the drug in 10% Tween 20 
by oral gavage for 32 days commencing 4 days before uninephrectomy. UNX and 
DOCA-salt controls received vehicle only. Rosuvastatin therapy attenuated the 
development of cardiovascular hypertrophy, inflammation, fibrosis and ventricular action 
potential prolongation, but did not modify hypertension or vascular dysfunction. We 
conclude that the pleiotropic effects of rosuvastatin include attenuation of aspects of 
cardiovascular remodelling in the DOCA-salt model of hypertension in rats without 
altering systolic blood pressure. 
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INTRODUCTION 
Although many drugs efficiently lower serum cholesterol levels, none have been more 
successful and well tolerated than the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors. The statins, as they are more commonly known, reduce 
cardiovascular mortality in primary and secondary prevention trials of coronary heart 
disease in patients with high or moderate hypercholesterolaemia [1-5] and even normal 
cholesterol levels [1, 5, 6]. This clinical benefit of statins may occur relatively early after 
initiation of therapy [3-5] and before any regression in atherosclerotic plaques can be 
detected [7]. In addition, their effects differ from those observed after the reduction of 
plasma cholesterol levels by surgical therapy [8]. These findings suggest that statins work 
by mechanisms additional to a decrement in plasma lipid concentrations and 
atherosclerotic plaque prevention or regression. Such pleiotropic effects include 
inhibiting the thrombogenic response and reducing oxidative stress and inflammation [9].  
 
More recently, several studies have documented that the pleiotropic effects of statins 
extend to the prevention of pathological cardiovascular remodelling in animal models of 
human disease, such as rat models of post-infarct heart failure [10] and type II diabetes 
mellitus [11]. However, it is unclear whether these cardioprotective effects are shared by 
all statins. This is especially important, considering the highly varied chemical structures, 
physicochemical and pharmacokinetic/metabolic properties of the many members of the 
statin family [12, 13] and the documented differences not only in their lipid lowering 
potential, but also in their nonlipid effects, particularly cardiovascular hypertrophy [14-
16].  
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 Rosuvastatin is a new synthetic and chemically distinct member of the statin family [13]. 
Clinical evidence has shown that rosuvastatin is the most effective statin with regards to 
lipid lowering [17]. However, whether rosuvastatin possesses the ability to exert similar, 
or more significant, beneficial effects on cardiovascular remodelling is yet to be 
established. There have been a number of publications showing rosuvastatin to be 
protective in cardiac ischemia-reperfusion injury models [18-20]. Consequently, we have 
investigated the potential pleiotropic effects of rosuvastatin on cardiovascular 
remodelling in the DOCA-salt model of hypertension in rats. 
 
METHODS 
Ethical Clearance 
All experimentation was approved by the Animal Experimentation Ethics Committee of 
The University of Queensland under the guidelines of the National Health and Medical 
Research Council of Australia. 
 
DOCA-salt hypertensive rats 
Male Wistar rats weighing 300-330g (~8 weeks old) were obtained from the Central 
Animal Breeding House of The University of Queensland. All rats were 
uninephrectomied. This was done under anaesthesia with intraperitoneal tiletamine (25 
mg/kg) and zolazepam (25 mg/kg)(Zoletil®) combined with xylazine (10 mg/kg)(Ilium 
Xylazil®). Kidneys were visualised by a left lateral abdominal incision. The left kidney 
was removed after ligation of adjoining renal vasculature and ureter with sutures. The 
 4
capsule was removed from the left kidney, which was then weighed. Uninephrectomized 
rats were given either no further treatment (UNX rats) or 1% NaCl in the drinking water 
with subcutaneous injections of deoxycorticosterone acetate (DOCA; 25mg in 0.4ml 
dimethylformamide every fourth day) (DOCA-salt rats). Rosuvastatin-treatment groups 
received 20mg/kg/day rosuvastatin in 10% Tween 20 by oral gavage for 32 days 
commencing 4 days before uninephrectomy. UNX and DOCA-salt controls received 
vehicle only. Experiments were performed 28 days after surgery.  
 
Assessment of Physiological Parameters 
Systolic blood pressure was measured by tail-cuff plethysmography in rats lightly 
anaesthetised with intraperitoneal tiletamine (10 mg/kg) and zolazepam (10 mg/kg). Rats 
were euthanased with pentobarbitone (200 mg/kg ip). Blood was taken from the 
abdominal vena cava, just caudal to the insertion of renal veins, centrifuged and the 
plasma immediately frozen. Plasma sodium and potassium concentrations were measured 
by flame photometry. The heart was removed and weighed immediately after death and 
expressed as a ratio of the tissue weight (mg) to the total body weight (g). Plasma levels 
of total cholesterol were measured by The University of Queensland Veterinary 
Pathology Services, Brisbane, Australia. 
 
Isolated Langendorff heart preparation 
Rats were anaesthetized with sodium pentobarbitone (100 mg/kg ip) and heparin (200 IU) 
was administered via the femoral vein. After allowing two minutes for the heparin to 
circulate, the heart was excised and placed in cooled (0°C) crystalloid perfusate (modified 
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Krebs-Henseleit solution of the following composition in mM: NaCl 119.1, KCl 4.75, 
MgSO4 1.19, KH2PO4 1.19, CaCl2 2.16, NaHCO3 25.0, glucose 11.0). A cannula was 
then placed in the heart with its tip immediately above the coronary ostia of the aortic 
stump. The cannula was used to perfuse the heart in a non-recirculating Langendorff 
fashion at 100cm of hydrostatic pressure. The perfusate temperature was maintained at 
37°C and bubbled with 95%O2 / 5%CO2. The apex of the heart was pierced to facilitate 
thebesian drainage and paced at 250 bpm.   
 
Left ventricular developed pressure was measured using a balloon catheter inserted into 
the left ventricle through the mitral orifice.  The catheter was connected via a three-way 
tap to a micrometer syringe and to a MLT844 Physiological Pressure Transducer 
(ADInstruments) and PowerLab data acquisition unit (ADInstruments).  The outer 
diameter of the catheter was similar to the mitral annulus to prevent ejection of the 
balloon during the systolic phase.  After a 5-minute stabilization period, steady-state left 
ventricular pressure was recorded from isovolumetrically beating hearts.  Increments in 
balloon volume were applied to the heart with left ventricular end-diastolic pressure 
recorded at approximately 0, 5, 10, 15, 20 and 30mmHg. At the end of the experiment, 
the atria and right ventricle were dissected away leaving the left ventricle and septum, 
which were blotted dry then weighed.   
 
Myocardial diastolic stiffness was calculated as the diastolic stiffness constant (k, 
dimensionless), the slope of the linear relation between tangent elastic modulus (E, 
dyne/cm2) and stress (σ, dyne/cm2) [21].  
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 Isolated thoracic aortic rings 
Thoracic aortic rings (approximately 4 mm in length) were suspended with a resting 
tension of 10 mN. Cumulative concentration-response curves were performed for 
noradrenaline and either acetylcholine or sodium nitroprusside in the presence of a 
submaximal (~70%) contraction to noradrenaline.  
 
Quantification of Left Ventricular Collagen 
Collagen content was determined by image analysis of picrosirius red-stained sections of 
the hearts [22]. In brief, transverse sections were stored initially in Telly’s fixative 
(100mL 70% ethanol; 5mL glacial acetic acid; 10mL formaldehyde) for 3 days, then 
transferred to modified Bouin’s solution (85 mL saturated picric acid; 5 mL glacial acetic 
acid; 10 mL 40% formaldehyde) for two days and then stored in 70% ethanol. 
 
Sections were subsequently embedded in wax and sliced into 10 µm sections. These were 
stained with picrosirius red (0.1% Sirius Red F3BA in picric acid). Slides were left in 
0.2% phosphomolybdic acid for 5 minutes, washed, left in picrosirius red for 90 minutes, 
then in 1 mM HCl for 2 minutes and 70% ethanol for 45 seconds. The stained sections 
were mounted with Depex and visualized using a Biorad MRC-1024 confocal laser-
scanning microscope with a Red/Texas Red filter with excitation at 568 nm and green 
emission at 609 nm. Images were acquired with an objective lens of 40x magnification 
and quantified using NIH-image software (National Institute of Health, USA). At least 4 
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areas from each heart were analysed and collagen levels expressed as a percentage of red 
area in each image. 
 
Histological collagen results were confirmed by hydroxyproline assay adapted from 
Stegemann and Stalder [23]. Approximately 2.5 and 5.0 mg samples of thoracic aorta and 
left ventricle respectively were dried for 6 hours at 40oC. Tissues and standards were then 
hydrolyzed in 6N HCl at 107oC for 18 hours. The acid was blown off by compressed air 
and the hydrolysate reconstituted in distilled water. Chloramine T reagent was added to 
each sample for the oxidation step to progress, followed by Ehrlich’s reagent to enable 
chromophore development. Absorbance of each sample was read at 550nm in a 
spectrophotometer and hydroxyproline content established from a standard curve.  
 
Width of Media in Thoracic Aorta 
The width of the media in the thoracic aorta of rats was measured by image analysis of 
picrosirius red-stained sections. Section preparation, staining, image acquisition and 
analysis were similar to those mentioned above. Three different areas of each aorta were 
measured and the results averaged. 
 
Immunofluorescence of ED-1 positive cells in the Left Ventricle 
Briefly, 5 µm thick sections were initially incubated with primary antibodies for rat 
macrophages (ED1; Serotec mouse anti-rat ED1 diluted 1:15). Omission of primary 
antibodies, and staining with an irrelevant mouse immunoglobulin of the same isotype, 
served as negative controls. Samples were then incubated with IgG-fluorescein 
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conjugated secondary antibody (Chemicon; diluted 1:200). Sections were counterstained 
with propidium iodide, mounted and visualized with a confocal laser-scanning 
microscope. A zero to four grading scale was used to classify the extent of ED-1 positive 
monocyte/macrophage infiltration in the left ventricle. 0 = no inflammatory cells present; 
1 = low level of inflammatory cells throughout the left ventricle; 2 = moderate levels of 
inflammatory cells throughout the left ventricle and concentrated in mild scarring; 3 = 
high levels of inflammatory cells throughout the left ventricle and concentrated in 
moderate scarring; 4 = high levels of inflammatory cells throughout the left ventricle and 
concentrated in heavy scarring. 
 
Microelectrode studies of isolated left ventricular papillary muscles 
Electrophysiological recordings of cardiac action potentials were obtained by 
microelectrode single cell impalements of ex vivo left ventricular papillary muscles. Rats 
were euthanased by carbon dioxide inhalation with subsequent exsanguination. The heart 
was removed and placed in chilled Tyrode’s physiological salt solution (in mM: NaCl 
136.9, KCl 5.4, MgCl2.H2O 1.0, NaH2PO4.2H2O 0.4, NaHCO3 22.6, CaCl2.2H2O 1.8, 
glucose 5.5, ascorbic acid 0.3, Na2-EDTA 0.05) bubbled with 95%O2 / 5%CO2, where 
the left ventricular papillary muscles were promptly dissected out. A stainless steel hook 
was placed through the valvular end of the papillary muscle, and a 30G needle was used 
to fix the apical end. The needle was subsequently embedded into a rubber base placed in 
a 1.0mL experimental chamber continuously perfused with carbogenated, warm 
(35±0.5oC) Tyrode’s solution at ~3 mL/min. The hook was attached to a modified sensor 
element (SensoNor AE801) connected to an amplifier (World Precision Instruments, 
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TBM-4). The muscle was stretched slowly to the required preload (3-5mN). Papillary 
contractions were induced by field stimulation (Grass SD-9) via electrodes on each side 
of the muscle (stimulation frequency 1 Hz; pulse width 0.5 ms; stimulus strength 20% 
above threshold). 
 
The muscle was allowed to equilibrate for 30 minutes then impaled with a microelectrode 
(World Precision Instruments, filamented borosilicate glass, outer diameter 1.5 mm) with 
a tip resistance of 5-15 MΩ when filled with 3M KCl. Perfusion and recording then 
continued for another 30 minutes. Action potential parameters measured were action 
potential duration (APD) at 20%, 50% and 90% of repolarization (APD20, ADP50 and 
APD90 respectively), action potential amplitude and resting membrane voltage. The 
reference electrode was a Ag/AgCl electrode. A Cyto 721 electrometer (World Precision 
Instruments) was used to record bioelectrical activity. All signals were recorded via a 
PowerLab 4S data acquisition unit (ADInstruments). Data were acquired, derived and 
analysed using Chart 4.3 software (ADInstruments). 
 
Data analysis 
All results are given as mean ± SEM. The negative log EC50 of the increase in force of 
contraction in mN was determined from the concentration giving half-maximal responses 
in individual concentration-response curves. These results were analysed by one-way 
analysis of variance followed by the Bonferroni post test to determine differences 
between treatment groups; p<0.05 was considered significant. 
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Drugs 
Deoxycorticosterone acetate, acetylcholine, sodium nitroprusside and noradrenaline were 
purchased from Sigma Chemical Company, St Louis, MO, USA. Rosuvastatin calcium 
was provided by AstraZeneca, U.K.. Noradrenaline, sodium nitroprusside and 
acetylcholine were dissolved in distilled water; deoxycorticosterone acetate was 
dissolved in dimethylformamide with mild heating.  
 
RESULTS 
Control and rosuvastatin-treated UNX rats gained similar weight over the 4 week 
protocol. Both DOCA-salt groups, on the other hand, failed to gain body weight in this 
period (Table 1). The systolic blood pressure of DOCA-salt rats rose significantly at 2 
weeks and even further at 4 weeks (Table 1). Rosuvastatin treatment had no effect on this 
developing hypertension in DOCA-salt rats. UNX rats exhibited no alterations in blood 
pressure (Table 1). Total plasma cholesterol concentration was significantly augmented 
in DOCA-salt rats, while rosuvastatin treatment normalized this parameter in these rats 
(Table 1). The concentration of plasma sodium was unaltered amongst the four rat 
groups; however, plasma potassium concentration was decreased in both control and 
treatment DOCA-salt groups (Table 1). 
 
DOCA-salt animals exhibited an increase in left ventricular mass that was attenuated by 
rosuvastatin treatment (Table 1). Fibrosis following an increased infiltration of 
inflammatory cells is characteristic of the DOCA-salt rat left ventricle [24]. We have 
shown that the left ventricular tissue of DOCA-salt animals exhibited considerable ED1-
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positive inflammatory cell infiltration compared to UNX controls, and this inflammation 
was prevented by rosuvastatin (Figure 2). The left ventricular tissue of DOCA-salt 
control rats was also found to be substantially fibrosed, as evidenced by a significant 
increase in both interstitial and perivascular left ventricular collagen area compared with 
UNX controls (Figure 1). Rosuvastatin treatment was successful in attenuating the 
increase in interstitial collagen area (Figure 1). The drug also normalized the perivascular 
collagen area of DOCA-salt rats (Figure 1). An alternative measure of cardiac fibrosis, 
hydroxyproline content, was also elevated in the left ventricle of DOCA-salt control rats 
in comparison to UNX animals (Figure 1). Once again, rosuvastatin treatment reduced 
this indicator of cardiac fibrosis (Figure 1). The isolated perfused hearts of DOCA-salt 
control rats exhibited an increased diastolic stiffness constant compared to UNX animals. 
Rosuvastatin treatment of these animals normalized this measure of cardiac stiffness 
(Table 1). 
 
Electrophysiological studies of isolated papillary muscles revealed no difference in 
resting membrane potential and action potential amplitude between UNX and DOCA-salt 
rats (Table 2). DOCA-salt rats showed significant electrical remodelling, manifested as 
prolonged action potential durations at 20%, 50% and 90% of repolarization (APD20, 
APD50 and APD90) (Table 2, Figure 4). Rosuvastatin treatment significantly attenuated 
this prolongation of APD90, but not APD20 or APD50 (Table 2, Figure 4). 
 
The thoracic aorta media width of DOCA-salt rats was found to be significantly increased 
compared to UNX rats, with rosuvastatin therapy attenuating this vascular hypertrophy 
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(Table 1). In contrast, the hydroxyproline content of these vessels was similar among 
groups (Table 1). Vascular smooth muscle dysfunction was evidenced by the reduced 
contractile response to noradrenaline, as well as the decreased relaxant response to 
sodium nitroprusside in isolated thoracic aortic rings of DOCA-salt rats compared to 
UNX controls (Figure 3A and C). There was also an increased potency of noradrenaline-
induced contraction in these rings (Figure 3A). Relaxant responses to acetylcholine were 
also reduced in hypertensive rats compared to their normotensive controls (Figure 3B). 
Rosuvastatin was without effect on these reduced responses to noradrenaline, sodium 
nitroprusside and acetylcholine in DOCA-salt rats (Figure 3A, B and C). Drug therapy 
augmented aortic responses to acetylcholine in UNX animals (Figure 3B). 
 
DISCUSSION 
Rats represent an excellent model for studying the pleiotropic effects of statins, as their 
lipid profile has been demonstrated to be refractory to statin therapy [25] and, in 
comparison to humans, their plasma lipid levels are relatively low. In the current study, 
we investigated the effects of a new HMG-CoA reductase inhibitor, rosuvastatin, on 
cardiovascular remodelling in the DOCA-salt model of hypertension in rats. We show for 
the first time that rosuvastatin attenuated left ventricular fibrosis, hypertrophy, 
inflammation and action potential prolongation and aortic medial hypertrophy, without 
antihypertensive action in this rodent model of end-organ damage. 
 
Statins have been reported to reduce blood pressure in a randomized, double-blind 
crossover trial in humans (pravastatin) [26] and hypertensive rodent models (simvastatin 
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and lovastatin) [27, 28], including DOCA-salt hypertensive mice (lovastatin) [29]. We, 
on the other hand, found that rosuvastatin was without effect on DOCA-salt-induced 
hypertension in rats. This difference may be related to model and species differences or 
the relative hydrophilicity of rosuvastatin limiting its uptake through their plasma 
membrane. However, independent of any anti-hypertensive effect, rosuvastatin attenuated 
the increase in left ventricular mass and medial hypertrophy of the thoracic aorta 
associated with DOCA-salt treatment. In the genetically hypertensive (GH) rat, 
fluvastatin had no effect on blood pressure, but significantly remodelled the mesenteric 
resistance and basilar arteries by reducing medial cross-sectional area and increasing 
lumen size [30]. Furthermore, long-term administration of simvastatin to rats with aortic 
stenosis inhibited left ventricular hypertrophy without effect on the elevated carotid mean 
arterial pressure [31]. Taken together, these data support the notion that a reduction of 
blood pressure is not the primary factor involved in the inhibitory effect of statins on 
cardiovascular hypertrophy. 
 
In the current study, rosuvastatin therapy reduced left ventricular monocyte infiltration. 
Such infiltration has been demonstrated to participate in the initiation and progression of 
cardiovascular pathology in the DOCA-salt model [24, 32]. HMG-CoA reductase 
inhibitors modulate several different components of the inflammatory cascade, 
particularly those involving leucocyte-endothelium interactions, such as the down 
regulation of cell adhesion molecule expression [9]. Indeed, rosuvastatin inhibited 
endothelial cell surface expression of the adhesion molecule P-selectin, and thus 
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attenuated leukocyte rolling, adherence and transmigration in normocholesterolaemic rat 
mesenteric venules [33]. 
 
Inflammation has also been shown to play a role in long-term pathological cardiovascular 
changes, such as matrix accumulation [34]. Hence the anti-fibrotic properties of 
rosuvastatin in DOCA-salt rats, manifest as reduced LV collagen and hydroxyproline 
contents and diastolic stiffness (an indirect measure of total collagen), may in part be due 
to a direct inhibitory effect of the drug upon monocyte/macrophage infiltration. This is 
supported by Ammarguellat and co-workers [24], who have identified inflammatory 
mediators as a major component of cardiac remodelling and critical to the progression of 
cardiac fibrosis in this model of mineralocorticoid-induced hypertension. Furthermore, 
Kagitani et al. [32] showed that tranilast, an anti-inflammatory drug, suppressed 
myocardial fibrosis via inhibition of cytokines, such as monocyte chemotactic protein-1 
and interleukin-6, and monocyte/macrophage infiltration in DOCA-salt rats. Taken 
together, these results suggest that pharmacological attenuation of the inflammatory 
response by rosuvastatin may, in part, be responsible for preventing myocardial fibrosis 
in DOCA-salt rats. This effect may also potentially translate to fibrosis-associated 
abnormalities, such as diastolic stiffness. Our previous studies with L-arginine, the NO 
precursor, and A-127722, a selective ETA-receptor antagonist, have shown attenuation of 
inflammatory cell infiltration, myocardial collagen deposition and diastolic stiffness [35, 
36]. 
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Action potential prolongation is a common electrophysiological disturbance in 
hypertrophied myocardium [37] and this includes DOCA-salt animals [38]. We show an 
approximate 2-fold increase in APD90 as a result of mineralocorticoid and salt treatment. 
It appears that depression of the calcium-independent transient outward K+ current (Ito) is 
responsible for the majority of this prolongation observed in DOCA-salt ventricular 
myocytes; an absence of enhanced Ito channel expression concurrent with hypertrophy 
resulted in a reduced channel density per unit surface area [38]. Furthermore, regression 
of LV hypertrophy in DOCA-salt rats normalized the Ito current and APD [38]. Thus, the 
observed attenuation of cardiac action potential prolongation by rosuvastatin is most 
likely secondary to its amelioration of left ventricular hypertrophy in these rats. This is 
supported by recent work from our laboratory demonstrating improvement in cardiac 
action potential prolongation in association with pharmacologic-induced regression of 
left ventricular hypertrophy in DOCA-salt rats [35, 36]. 
 
Hypercholesterolaemia has been shown to induce endothelial dysfunction, an attribute of 
the initial stages of atherosclerosis [39]. It is not surprising then that statins have been 
shown to be useful in the reversal of endothelial dysfunction, as documented with non-
invasive techniques [40-42]. This effect, however, may also be partly independent of a 
reduction in cholesterol levels [41]. Nonetheless, DOCA-salt rats develop endothelial 
dysfunction because of severe hypertension, rather than lipid disorders. In the current 
study, rosuvastatin was without effect on endothelial dysfunction in DOCA-salt animals. 
This may be attributed to species differences and variation in the capacity of statins to 
penetrate vascular cell membranes, but it is also conceivable that blood pressure lowering 
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may be a prerequisite for the improvement of endothelial dysfunction in DOCA-salt 
hypertension. However, it is difficult to make a clear distinction on this anomaly, as a 
result of the reduced relaxant response to sodium nitroprusside, as well as noradrenaline, 
in DOCA-salt rats, indicating a primary dysfunction of vascular smooth muscle. 
Rosuvastatin did, however, improve endothelium-dependent acetylcholine-induced 
vascular relaxations in normotensive UNX rats. 
 
The exact mechanism by which rosuvastatin attenuates cardiovascular remodelling in 
DOCA-salt animals is beyond the scope of this study. However, in addition to cholesterol 
reduction, HMG-CoA reductase inhibition also decreases mevalonate synthesis leading to 
changes in isoprenoid metabolism [43]. Because isoprenoid intermediates are important 
factors for the post-translational modification, maturation and membrane translocation of 
various regulatory proteins, such as the low molecular weight GTP-binding proteins of 
the Ras superfamily [44], it is possible that rosuvastatin-induced attenuation of 
cardiovascular remodelling is mediated by modifying the downstream products of 
cholesterol and, hence, mevalonate metabolism. In support of this, statins have been used 
to establish the functional involvement of the mevalonate pathway and these G-proteins 
in the regulation of cardiac myocyte [45], fibroblast [46] and vascular smooth muscle cell 
[47] mitogenesis. Furthermore, data suggests that Ras upregulation contributes to the 
development of DOCA-salt hypertension and associated reno-vascular hypertrophy and 
interstitial fibrosis [48] and this G-protein has also been implicated in the 
mineralocorticoid-induced mitogenesis of fibroblasts [49]. 
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An elevated total cholesterol concentration has been demonstrated previously with 
DOCA-salt treatment in rats [50], and our results confirm this. The exact mechanism 
behind this elevation is unclear, but HMG-CoA inhibition by rosuvastatin normalized 
plasma levels in our rats, suggesting increased endogenous cholesterol synthesis. 
Whether these raised cholesterol levels and their subsequent abrogation by rosuvastatin 
had any effect on cardiovascular remodelling in this model is unlikely, but cannot be 
ruled out. 
 
CONCLUSION 
In conclusion, we show for the first time that rosuvastatin attenuates cardiovascular 
remodelling, especially aortic medial thickening, myocardial inflammation and fibrosis, 
left ventricular hypertrophy and action potential prolongation, in DOCA-salt hypertensive 
rats without lowering blood pressure. These findings indicate the pleiotropic effects of 
the statins in rats that could explain, at least in part, improvements in survival and quality 
of life observed in patients treated with statins. Furthermore, the actions of rosuvastatin 
on cardiac remodelling may represent potential applications of statins beyond lipid 
lowering and atherosclerosis prevention or regression. Future studies using a therapeutic 
approach, that is a reversal protocol by commencing treatment after the onset of disease, 
are necessary to show the clinical relevance of these findings. 
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Table 1: Physiological parameters in UNX, DOCA-salt and RSV-treated rats. 
 
DATA UNX UNX+RSV DOCA-salt DOCA-
salt+RSV 
Initial Body 
Weight (g) 
314±3 
(n=10) 
316±3 
(n=10) 
316±4 
(n=12) 
317±3 
(n=12) 
Final Body 
Weight (g) 
404±7 
(n=10) 
410±6 
(n=10) 
316±7* 
(n=12) 
335±7* 
(n=12) 
0 week Systolic 
Blood Pressure 
(mmHg) 
123±6 
(n=10) 
121±4 
(n=10) 
126±5 
(n=9) 
118±4 
(n=8) 
2 week Systolic 
Blood Pressure 
(mmHg) 
123±6 
(n=10) 
117±4 
(n=10) 
160±9* 
(n=9) 
155±10* 
(n=8) 
Final Systolic 
Blood Pressure 
(mmHg) 
122±4 
(n=10) 
118±3 
(n=10) 
188±3* 
(n=9) 
194±7* 
(n=8) 
LV+septum 
Weight (mg/g) 
1.86±0.04 
(n=10) 
1.92±0.04 
(n=10) 
3.07±0.14* 
(n=12) 
2.68±0.10*#
(n=10) 
Plasma 
Cholesterol 
Concentration 
(mM/L) 
2.0±0.1 
(n=7) 
1.8±0.1 
(n=7) 
5.1±0.5* 
(n=7) 
1.9±0.3#
(n=7) 
Plasma Na+ 
Concentration 
(mM) 
130.4±1.1 
(n=10) 
130.1±0.3 
(n=10) 
136.3±0.8 
(n=10) 
133.5±1.0 
(n=10) 
Plasma K+ 
Concentration 
(mM) 
4.2±0.3 
(n=10) 
4.0±0.2 
(n=10) 
2.2±0.1* 
(n=10) 
2.1±0.3* 
(n=10) 
Diastolic 
Stiffness 
Constant (κ) 
21.4±0.4 
(n=10) 
21.9±0.4 
(n=9) 
24.9±0.4* 
(n=12) 
21.5±0.5#
(n=7) 
Aortic Media 
Thickness (µm) 
84.1±1.4 
(n=7) 
82.5±1.6 
(n=10) 
114.8±4.8* 
(n=11) 
100.8±4.0*# 
(n=7) 
Aortic 
Hydroxyproline 
Content 
(µg/mg) 
15.6±0.7 
(n=9) 
15.3±0.5 
(n=9) 
15.4±0.4 
(n=10) 
15.2±0.4 
(n=10) 
*p<0.05 compared to UNX, #p<0.05 compared to DOCA-salt 
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Table 2: Cardiac electrophysiological parameters in UNX, DOCA-salt and RSV-treated 
rats. 
 
DATA UNX UNX+RSV DOCA-salt DOCA-
salt+RSV 
Resting Membrane 
Potential (mV) 
-76±4 
(n=6) 
-75±3 
(n=6) 
-68±2 
(n=6) 
-70±2 
(n=7) 
Action Potential 
Amplitude (mV) 
97±2 
(n=6) 
92±3 
(n=6) 
93±2 
(n=6) 
89±2 
(n=7) 
APD20 (ms) 8.7±0.3 
(n=6) 
6.9±0.3 
(n=6) 
18.2±2.7* 
(n=6) 
14.4±2.1 
(n=7) 
APD50 (ms) 18.9±0.9 
(n=6) 
17.0±0.9 
(n=6) 
47.7±5.1* 
(n=6) 
35.6±4.0* 
(n=7) 
APD90 (ms) 46.0±1.0 
(n=6) 
51.4±3.9 
(n=6) 
114.4±2.9* 
(n=6) 
95.2±3.1*#
(n=7) 
*p<0.05 compared to UNX, #p<0.05 compared to DOCA-salt 
APD20, APD50 and APD90 = Action potential duration at 20%, 50% and 90% of 
repolarization respectively 
 
 
 
                                              
FIGURE 1 
 25
 26
FIGURE 2 
FIGURE 3 
 27
FIGURE 4 
 
 28
FIGURE 1: Representative picrosirius red stained confocal images of left ventricular 
interstitial collagen from UNX control (A), rosuvastatin-treated UNX (B), DOCA-salt 
control (C), and rosuvastatin-treated DOCA-salt (D) rats (magnification 40x). Graphical 
representations of left ventricular interstitial collagen area (E), perivascular collagen area 
(F) and hydroxyproline content (G). (* p < 0.05 vs UNX; # p < 0.05 vs DOCA-salt). 
 
FIGURE 2: Representative confocal images of left ventricular tissue showing 
immunofluorescent ED-1 positive monocyte/macrophages in UNX control (A), 
rosuvastatin-treated UNX (B), DOCA-salt control (C), and rosuvastatin-treated DOCA-
salt (D) rats (magnification 20x). Graphical representation of ED-1 positive 
monocyte/macrophage left ventricular infiltration grading. (* p < 0.05 vs UNX; # p < 
0.05 vs DOCA-salt). 
 
FIGURE 3: Concentration-response curves to noradrenaline (A) for UNX control (filled 
squares, -log EC50 7.0±0.1, n=12), rosuvastatin-treated UNX (open squares, -log EC50 
7.1±0.1, n=13), DOCA-salt control (filled triangles, -log EC50 7.9±0.1*, n=11) and 
rosuvastatin-treated DOCA-salt (open triangles, -log EC50 7.9±0.1*, n=11) rats. 
Concentration-response curves to acetylcholine (B) for UNX control (filled squares, -log 
EC50 6.6±0.1, n=11), rosuvastatin-treated UNX (open squares, -log EC50 6.8±0.1, 
n=12), DOCA-salt control (filled triangles, -log EC50 6.5±0.1, n=12) and rosuvastatin-
treated DOCA-salt (open triangles, -log EC50 6.6±0.1, n=11) rats. Concentration-
response curves to sodium nitroprusside (C) for UNX control (filled squares, -log EC50 
7.4±0.1, n=12), rosuvastatin-treated UNX (open squares, -log EC50 7.3±0.1, n=13), 
DOCA-salt control (filled triangles, -log EC50 7.1±0.1, n=13) and rosuvastatin-treated 
DOCA-salt (open triangles, -log EC50 7.1±0.1, n=9) rats. (* p < 0.05 vs UNX; # p < 0.05 
vs DOCA-salt). 
 
FIGURE 4: Representative cardiac action potential recordings from UNX control 
(green), rosuvastatin-treated UNX (blue), DOCA-salt control (red) and rosuvastatin-
treated DOCA-salt rats (black). Action potential prolongation can be observed in DOCA-
salt controls and this can be attenuated by rosuvastatin treatment. 
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